StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) income statement

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3068% below fair value
$0.37−0.02 (-4.47%)

Close on Nov 20, 2026Market cap $57.13MP/E –Yield –

See a number that looks wrong?